Alirocumab is a fully human mAb to PCSK9 that has shown considerable promise in Phase 2 trials[21–23] and is currently in Phase 3 trials for the treatment of hypercholesterolemia and reduction of cardiovascular events. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.